Category Archives: Cell Therapy

MissouriCuresEvents_Oct2012_Dr.MarieCsete
"The stem cell therapy race: roadblocks to the finish line", as presented by Dr. Marie Csete at The Danforth Center on behalf of Missouri Cures Education Foundation #39;s Speaker Series in October, 2012.From:MissouriCuresEventsViews:4 0ratingsTime:51:36More inNonprofits Activism

See the article here:
MissouriCuresEvents_Oct2012_Dr.MarieCsete - Video

Robert Toves Testimonial (Parkinson #39;s Disease) Stem Cell Therapy
Robert Toves is a patient at Integra Medical Center, Mr.Toves suffers of Parkinson #39;s disease and has come to try Dr.Gonzalez method of stem cell therapy, just less than an hour after the stem cell therapy great results seem to show.From:OmarGonzalezMDViews:8 0ratingsTime:05:58More inScience Technology

View original post here:
Robert Toves Testimonial (Parkinson's Disease) Stem Cell Therapy - Video

Posted by Juan Carlos Fanjul/CBS 12 News

WEST PALM BEACH, Fla-- It may look like boring exhibits and the usual convention type crowds, but in this hall life-saving science is being talked about and big money will eventually make it into the local economy.

"Probably injecting over a million dollars in the local economy and it's a showcase for Palm Beach County," said event organizer Bernard Siegel.

Siegel says over 1,200 scientists from more than 40 countries are at the Palm Beach County Convention Center this week for the 8th annual World Stem Cell Summit.

With the opening of Max Planck this week and the continued growth of Scripps in northern Palm Beach County and Torrey Pines in Saint Lucie County, Siegel says this convention means a coming of age for the region's biotech sector.

"This is considered the largest meeting in the country and we have the top scientists," he added.

Claudia Zylberberg owns AKRON Biotech, a Boca Raton-based supplier of raw materials for stem cell therapy she started just a few years ago.

"I realized early on there was a lot of potential for growth and this turned out the right place to be," she said.

Doctor Joshua Hare leads the Interdisciplinary Stem Cell Institute for the University of Miami and says he's noticed growth too.

"We don't have the critical mass of Baltimore or Boston and we would like to see that, but you are seeing the seeds of that right now," he said. World Stem Cell Summit Fuels Economy

More:
World Stem Cell Summit Fuels Economy

We have permission to take others off the website, http://www.worldstemcellsummit.com/featured-speakers

World Stem Cell Summit organizer Bernie Siegel has joined forces with scientists from the University of Miami to host the 1,000 attendees from 34 countries expected at the summit in West Palm Beach this week.

Each have made discoveries in stem-cell research that could make a difference for those suffering from diabetes and heart disease.

Dr. Joshua Hare, a cardiologist at UM's Miller School of Medicine, has been a pioneer the use of stem cell therapy to repair damaged hearts. Recently, he completed a clinical trial where scarring was reduced by 33 percent in patients who had previous heart attacks.

"The No. 1 reason for heart failure is because of cardiac scarring. If you can remove it and replace with new tissue, that's very exciting," he said.

Dr. Camillo Ricordi, director of UM's Diabetes Research Institute, developed an experimental procedure that has improved blood glucose control and the quality of life of some Type 1 diabetics. But the procedure involves organ donors.

Ultimately, he's seeking a cure that involves "replacing cells in Type 1 diabetics with insulin-producing cells that are in our own body."

"I definitely think the cure is within our reach. We've had so much progress within the last three years," said Ricordi, who posts updates on his research on facebook.com/DiabetesResearch.org.

Other top speakers at the summit include:

Dr. George Daley, director of the Stem Cell Transplantation Program, HHMI/Children's Hospital in Boston where he specializing in research and drug development for those with leukemia and genetic blood disorders.

View post:
World stem cell event opens in West Palm Beach

Company's ability to do something nobody has done before confirms world-leader status.

Scottsdale, AZ (PRWEB) November 30, 2012

In the companys news yesterday,

International Stem Cell Corp. has achieved a critical milestone towards the clinical development of its non-embryonic stem cell therapy.

Through much dedication and hard work, the companys research and development team has created the worlds first human clinical-grade stem cell lines that can be immune-match to millions of individuals. ISCOs existing research-grade parthenogenetic stem cell lines, one of which may be an immune-match to approximately 70 million people, are being used in pre-clinical development. ISCO is now in a position to conduct clinical trials in the United States.

Weve been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and Im excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. Im optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide, stated Dr. Semechkin, CEO and Co-Chairman of the Board.

Created using ISCOs proprietary technology, the new stem cell lines represent the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is necessary to conduct clinical development programs.

Independent third-party testing has confirmed the new lines to be homozygous in the HLA coding regions. This means that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection; a distinct clinical advantage over embryonic stem cells. The company anticipates the new lines to immune-match millions of individuals. They will be added to ISCOs existing bank and provide a platform from which to develop cells and tissue for clinical use.

The importance of this breakthrough cannot be overstated, emphasized Dr. Craw, Executive Vice President of ISCO. Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company.

About QualityStocks

More here:
QualityStocks News - International Stem Cell Corp. Advances Groundbreaking Stem Cell Therapy with Distinct Advantages ...

Procedure Combines Point-of-Care Stem Cell Therapy and Enriched Mesenchymal Stem Cell Injection

NAMPA, ID--(Marketwire - Nov 29, 2012) - Veterinarians from Idaho Equine Hospital, including Dr. William Maupin and Dr. Stuart Shoemaker, performed the first-ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

This injury can be challenging for veterinarians to successfully treat and return the horse to athletic competition.

The veterinary team and the scientific team at Stemlogix, LLC determined that the best treatment protocol would be to treat him with point-of-care stem cell therapy using the Stemlogix In-Clinic Regenerative Medicine System and then perform a follow up treatment a few weeks later using culture expanded mesenchymal stem cells. He received a dose of the point-of-care stem cell therapy three weeks ago and three weeks later received an injection of culture expanded mesenchymal stem cells.

Stemlogix, LLC pioneered the landmark stem cell therapy treatment regimen and this is the first time this combination stem cell therapy treatment has ever been performed on a horse. The team that treated the horse believes this revolutionary treatment protocol will give him the best chance for an improved quality of life and provides the best opportunity for restoring the injured tissue back to its normal structure instead of healing with scar tissue.

"Due to the severity of the injury and the poor circulation present in the sesamoidean ligament we elected to perform a two-step therapeutic approach," said Dr. Maupin. "We first injected adipose derived stem cell therapy produced patient-side to initiate an environment of healing.

"In addition, we injected culture expanded mesenchymal stem cells. This secondary expanded and enriched mesenchymal stem cell therapy treatment may further restore normal tissue structure or actual ligament tissue."

To provide him with this groundbreaking treatment, two small fat samples were taken from the base of his tail via a minimally invasive lipoaspirate procedure. Fat tissue is the richest source of stem cells for both human patients and animal patients. One of the tissue samples was processed on-site to provide a same-day, point-of-care stem cell treatment while the other tissue sample was sent to the Stemlogix state-of-the-art cGMP laboratory where the mesenchymal stem cells were isolated and expanded for three weeks. A portion of his stem cells were also cryopreserved for future use.

The Stemlogix In-Clinic Regenerative Medicine System rapidly produces a composition of stem cells at the point-of-care containing an abundance of mesenchymal stem cells, endothelial progenitor cells, among other cell types. This assortment of stem cells provides additional growth factors and therapeutic proteins to stimulate healing. This system offers veterinarians an optimal treatment tool that is convenient and effective in treating debilitating equine diseases and injuries.

On the other hand, the culture expanded stem cell therapy contains a high number of purified mesenchymal stem cells which makes this therapy better suited for treating specific indications such as orthopedic injuries, autoimmune diseases and other degenerative diseases. Mesenchymal stem cells are multi-potent or have the ability to form into a variety of new tissues such as bone, cartilage, ligaments, and tendons.

See more here:
Stemlogix Reports Idaho Veterinarians Perform First in U.S. Combination Regenerative Medicine Treatment on Injured Horse